Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.4%

Neg 0% Neu 89.4% Pos 0%

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.

Comments

No comments yet. Be the first!